You can finally forget about those unaesthetic acoustic ceilings. Here is Pyrymyd, an advanced all-in-one product, able to create various scenarios and personalized micro ambiences. Therefore, it is a ...

8, 2024. (AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of ...

Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Johnson & Johnson on Monday said it has agreed to acquire Intra-Cellular Therapies, a developer of drugs for diseases of the brain, for $132 per share, or about $14.6 billion. The announcement of the ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

Johnson & Johnson JNJ4.13%increase; green up pointing triangle agreed to acquire mental-illness drug developer Intra-Cellular Therapies ITCI-0.11%decrease; red down pointing triangle for about $15 ...

Johnson & Johnson is in talks to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central nervous system disorders, people familiar with the matter said. A ...

Jan 12 (Reuters) - Drug maker Johnson & Johnson (JNJ.N), opens new tab is exploring a bid to acquire Intra-Cellular Therapies (ITCI.O), opens new tab, a biopharmaceutical company, Bloomberg News ...

The potential acquisition comes as J&J seeks to bolster its portfolio. Credit: Skorzewiak/Shutterstock. Johnson & Johnson (J&J) has announced it will acquire Intra-Cellular Therapies, a company ...